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SYMPOSIUM: 
  
BALANCING SCIENCE AND POLITICS: 
THE CHALLENGES OF 
IMPLEMENTING  
MEDICAL MARIJUANA LAWS 
INTRODUCTION 
At the time of this publication, at least eighteen states and the District of 
Columbia have passed laws that legalize the use of medical marijuana. Many other 
states and policymakers are considering similar legislation. These laws are varied 
in nature and face numerous implementation challenges, including resistance from 
local, state, and federal government agencies; challenges from a medical and 
pharmaceutical standpoint; and inadequate funding and infrastructure. On Friday, 
April 13, 2012, the University of Maryland Francis King Carey School of Law’s 
Law & Health Care Program, the Network for Public Health Law, and the 
University of Maryland School of Pharmacy’s Center for Drugs and Public Policy 
jointly sponsored a conference intended to raise and address these and other issues 
surrounding the rapidly evolving landscape of state medical marijuana laws and 
programs.  
Entitled “Balancing Science and Politics: The Challenges of Implementing 
Medical Marijuana Laws,” this conference brought together a variety of speakers 
with expertise in pharmacy and drug policy, state-level public health policy, federal 
regulation of marijuana, and state medical marijuana legislation. State legislators, 
reform leaders, health practitioners, and academics met and presented on topics 
including preemption issues in state decriminalization efforts, legal issues relating 
to marijuana dispensaries, public health implications of medical marijuana 
decriminalization, monitoring of the use of medical marijuana, and medical 
marijuana in health care facilities. 
Participants had the opportunity to share their expertise, relate their 
experiences with the emerging legal framework in their states, learn from a variety 
of other experts with diverse scholarly and professional perspectives, and discuss 
future legislative efforts. The Symposium articles published in this issue of the 
Journal of Health Care Law & Policy, authored by conference participants, are 
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outgrowths of the conference, and provide a deeper look into some of the crucial, 
emergent topics surrounding these laws.  
Robert A. Mikos, Professor of Law and Director of the Program in Law & 
Government at Vanderbilt University Law School, presented a guide to the 
complex and often-confusing issue of federal preemption of medical marijuana 
laws. In his article, Preemption Under the Controlled Substances Act, he offers an 
up-to-date and in-depth analysis of states’ authority to enact medical marijuana 
laws in light of preemption questions raised by the federal Controlled Substances 
Act. 
Karen O’Keefe, Director of State Policies for the Marijuana Policy Project, 
offered valuable insight into the current landscape and emerging trends in state 
medical marijuana legislation at the conference. In her article, State Medical 
Marijuana Implementation and Federal Policy, she examines the chilling effect of 
shifting federal policy on medical advancement and legal protections for patients. 
She also suggests federal policy reforms to improve the relationship between the 
federal and state governments and medical marijuana patients and providers. 
Linda Simoni-Wastila, a professor and Vice Chair of Research at the 
University of Maryland School of Pharmacy in the Department of Pharmaceutical 
Health Services Research, presented on the consumption and consequences of 
medical marijuana from an epidemiological perspective. Francis B. Palumbo, a 
professor at the University of Maryland School of Pharmacy and the Executive 
Director of the Center on Drugs and Public Policy, spoke on the issue of how to 
monitor and regulate medical marijuana. Their paper, Medical Marijuana 
Legislation: What We Know—and Don’t, reviews and critiques current and 
potential frameworks for implementing and evaluating medical marijuana 
legislation. 
The Journal of Health Care Law & Policy prides itself on being one of the 
few scholarly journals that bridges legal, public policy, and scientific fields. The 
articles included in this Symposium issue do just that, providing timely and 
nuanced perspectives on the crucial medical and legal policy questions raised by 
the ever-increasing number of state medical marijuana laws. The viewpoints 
represented within this issue of the Journal include the pharmaceutical, 
constitutional, and policy aspects of such legislation.  
This issue, and every issue, of the Journal of Health Care Law & Policy, 
provides scholarly insight into leading health law and policy issues from an 
interdisciplinary perspective. The Editorial Board and Staff of the Journal hope 
that this Symposium issue stimulates discussion and provides in-depth analysis of 
this complex and controversial area of law. On behalf of the Journal of Health 
Care Law & Policy, I would like to thank the University of Maryland Francis King 
Carey School of Law’s Law & Health Care Program, the Network for Public 
Health Law, and University of Maryland School of Pharmacy’s Center for Drugs 
and Public Policy, as well as the conference participants and others who facilitated 
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this discussion. On behalf of the Journal’s Editorial Board, I would also like to 
thank our Faculty Advisor, Diane Hoffmann, Director of the Law & Health Care 
Program, and Virginia Rowthorn, Managing Director of the Law & Health Care 
Program, for their continued guidance and support. I also extend my deepest 
gratitude to the Journal Staff and Editorial Board for their hard work, dedication, 
and support during the production of this issue.  
 
Rebecca Hall  
Editor in Chief 
 
